

# CorNotes

## CVI SEMINAR

The next CVI Seminar will be held on **Thursday, June 21, 2007 at 4:00 pm** in **The Van Kampen Conference Center, Building 110, Room 6274**. The featured speaker will be:

**William F. Jackson, Ph.D.**  
**Professor of Pharmacology and Toxicology**  
**Michigan State University**  
**Lansing, MI**

The title of Dr. Jackson's lecture is:

**" Ion Channels And Regulation Of Arteriolar Tone"**

For further information about the CVI Seminar Series, contact Dr. Leanne Cribbs at x72817.

## CVI JOURNAL CLUB

June 14.....Dr. Henderson

CVI Journal Club is held at 12:00 noon in the CVI Research Division Conference Room, Room 5215. For further information, contact Dr. Ken Byron at x72819.

## RECENT PUBLICATIONS FROM THE CVI

Jeske WP, McDonald MK, Hoppensteadt DA., Bau AC, Mendes A, Dietrich CP, Walenga JM, and Coyne E. Isolation and characterization of heparin from tuna skins. *Clin Appl Thrombosis/Hemostasis* 13(2):137-145, 2007.

Coaxum SD, Griffin TM, Martin JL, Mestrl R. Influence of PKC- $\alpha$  overexpression on HSP70 and cardioprotection. *Am. J. Physiol. Heart Circ. Physiol.* 292(5):H2220-H2226, 2007.



**LOYOLA  
 MEDICINE**

*Loyola University Chicago  
 Stritch School of Medicine*

## CARDIOLOGY – CVI RESEARCH DIVISION BASIC SCIENCE SEMINAR

The Cardiology Division and the CVI Research Division are sponsoring a series of joint seminars by Loyola Faculty. The following seminar is scheduled at **7:30 am** in the **Van Kampen Conference Center**:

June 21.....Dr. Allen Samarel

The title of Dr. Samarel's talk is:

**"T3 Therapy in Experimental Heart Failure"**

For further information, contact Dr. Samarel at x72821.

## FREEDOM CLINICAL TRIAL

Dr. Fred Leya of the section of Interventional Cardiology is the Principal Investigator conducting the FREEDOM clinical trial. This is an NIH-sponsored project for which Mount Sinai School of Medicine is the coordinating center.

FREEDOM (Future revascularization and evaluation in patients with diabetes mellitus: optimal management of multivessel disease) is a multi-center, randomized trial. The main objective is to evaluate whether percutaneous coronary intervention (PCI) with drug-eluting stenting (PCI/DES) is more or less effective than the existing standard of care, coronary artery bypass surgery (CABG). Potential participants are diabetic patients with multivessel disease.

Diabetes mellitus, either Type-I or Type-II, is a very strong risk factor for the development of CAD and stroke. Eighty percent of all deaths among diabetic patients are due to atherosclerosis, compared to 30% in non-diabetic patients. Despite recent reductions in cardiovascular events among adults with diabetes, the absolute risk of cardiovascular events remains two-fold greater than among non-diabetic individuals.

Coronary revascularization procedures have become a mainstay of therapy for CAD patients, providing both symptomatic relief and mortality reduction in certain anatomic subsets. Several studies have attempted to rationalize the use of different revascularization techniques by comparing them to medical therapy and to each other in various clinical settings. These studies have not specifically targeted diabetic patients.

For more information or to alert the Interventional Cardiology team of potential participants, please contact the project's coordinator, Sally Botkin, at 708-327-2494.